A5076760094- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Medical Imaging and Pathology Studies
- Advanced Chemical Sensor Technologies
- Indoor Air Quality and Microbial Exposure
- Asthma and respiratory diseases
- Inhalation and Respiratory Drug Delivery
- Sarcoidosis and Beryllium Toxicity Research
- Occupational and environmental lung diseases
- Neonatal Respiratory Health Research
- Dysphagia Assessment and Management
- Nematode management and characterization studies
- Respiratory and Cough-Related Research
- Air Quality Monitoring and Forecasting
- Respiratory viral infections research
- IL-33, ST2, and ILC Pathways
- Histiocytic Disorders and Treatments
- Congenital Diaphragmatic Hernia Studies
- Fungal Plant Pathogen Control
- Occupational exposure and asthma
- Transplantation: Methods and Outcomes
- Gas Sensing Nanomaterials and Sensors
Hospital Universitari Germans Trias i Pujol
2021-2025
Hospital de Sant Pau
2018-2024
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2024
Universitat Autònoma de Barcelona
2024
Hospital Arnau de Vilanova
2021-2022
Respiratory Clinical Trials
2021
Institut de Recerca Sant Pau
2021
Patients with severe COVID-19 may develop lung fibrosis. Pirfenidone is an anti-fibrotic drug approved for idiopathic pulmonary The efficacy and safety of pirfenidone in patients fibrotic interstitial changes after recovery from pneumonia was evaluated. Phase 2, double-blind, placebo-controlled, Spanish multicenter clinical trial randomized to receive or placebo (2:1) 24-weeks. primary endpoint the proportion that improved, considered when percent change forced vital capacity (FVC) ≥10%...
Pulmonary fibrosis involves various types of immune cells and soluble mediators, including TGF-β IL-35, a recently identified heterodimeric cytokine that belongs to the IL-12 family. However, effect regulatory IL-35 may play an important role in fibrotic diseases. The aim this paper is explore immunoregulatory development interstitial lung disease (ILD). To gain better understanding issue, concentrations different profibrotic cytokines (F-ILD) non-fibrotic (NF-ILD) patients by ELISA were...
Interstitial lung diseases (ILDs) are characterized by inflammation or fibrosis of the pulmonary parenchyma. Despite involvement immune cells and soluble mediators in fibrosis, influence antimicrobial peptides (AMPs) remains underexplored. These effector molecules display a range activities, which include immunomodulation wound repair. Here, we investigate role AMPs development ILD. We compare concentration different cytokines 46 fibrotic (F-ILD) 17 non-fibrotic (NF-ILD) patients ELISA using...
There are few studies investigating the clinical profile of older patients with interstitial lung disease (ILD), so this study investigated characteristics population diagnosed ILD.
To investigate the prognostic impact of early readmission (30 days) on hospitalized patients with Interstitial Lung Disease (ILD).Observational study analysing a cohort in respiratory ward at University Hospital. Demographic, clinical data and survival status were collected from patients' records. Early was defined as hospitalization within 30 days after patient's discharge. The primary outcome 90-day 1-year all-cause mortality.Between 2013 to 2016, total 2.238 admitted 98 (%) had diagnosis...
Background: Bronchoalveolar lavage (BAL) is a technique classically used for the study of diffuse interstitial lung diseases (DILDs). Given recent advances in diagnosis DILD by transbronchial cryobiopsy (TBCB), it relevant to assess what BAL can contribute TBCB. Patients and Methods: This retrospective descriptive that included patients with who, between 2013 2017, underwent TBCB same bronchoscopy intervention. We evaluated complementary information provided facilitated multidisciplinary...
The presence of autoantibodies against extractable nuclear antigens (ENAs) in bronchoalveolar lavage (BAL) has been demonstrated a previous series 155 patients with interstitial lung disease (ILD). <b>Aim:</b> to analyze the clinical, functional, and radiological differences subgroup diagnosed Interstitial Pneumonia Autoimmune Features (IPAF) connective tissue disease-related ILD (CTD-ILD) who presented positivity for ENAs BAL (ENAs+) compared those negative at 3 years follow-up (ENAs -)....
Abstract Background Pulmonary Langerhans cell histiocytosis (PLCH) is a rare interstitial lung disease (ILD) associated with smoking, whose definitive diagnosis requires the exclusion of other forms ILD and compatible surgical biopsy. Bronchoalveolar lavage (BAL) commonly proposed for ILD, including PLCH, but diagnostic value this technique limited. Here, we have analyzed levels panel cytokines chemokines in BAL from PLCH patients, order to identify distinct immune profile discriminate...